High-quality and affordable healthcare at the train station. Why not?

The CEO of Hackensack Meridian Health shares how innovative approaches to healthcare delivery will create greater ...

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting ...

Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows. CARMEL, ...

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 ...

Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage ...

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer ...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission ...

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for ...

Ensure your health is in the right hands

For families looking to get a comprehensive autism or ADHD assessment for a child, young person or adult, KT Healthcare is a ...

Medicus Pharma Ltd: Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs ...